EpiCept Corporation Amends DURECT Corporation Bupivacaine Patch Licensing Agreement

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has amended its December 20, 2006 licensing agreement with DURECT Corporation granting DURECT exclusive, worldwide rights to certain EpiCept intellectual property for a transdermal patch containing bupivacaine for the treatment of back pain.
MORE ON THIS TOPIC